Bacterium and extracts of said bacterium and the use of same in therapy

US9486486B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-9486486-B2
Application numberUS-201113997022-A
CountryUS
Kind codeB2
Filing dateDec 22, 2011
Priority dateDec 22, 2010
Publication dateNov 8, 2016
Grant dateNov 8, 2016

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

The present invention relates to a novel bacterial strain isolated and characterized from groundwater. The invention also relates to bacterial extracts and to the therapeutic use of same, notably in the context of the treatment of inflammations.

First claim

Opening claim text (preview).

The invention claimed is: 1. A composition comprising a bacterial extract as an active ingredient and a pharmaceutically acceptable carrier, wherein the bacterial extract is obtained from a suspension of bacteria, and wherein said bacteria of the suspension is a nonpathogenic Gram-negative bacterium belonging to the class Betaproteobacteria, subfamily Neisseriaceae, and characterized in that a nucleotide sequence of a 16S rRNA gene of said bacterium includes sequence SEQ ID NO: 1. 2. The composition according to claim 1 , wherein said bacterium of the bacterial extract is the bacterium deposited with the CNCM on Apr. 8, 2010, under the reference 1-4290. 3. Bacterial extract obtained from a suspension of bacteria, wherein said bacteria of the suspension is a nonpathogenic Gram-negative bacterium belonging to the class Betaproteobacteria, subfamily Neisseriaceae, and characterized in that a nucleotide sequence of a 16S rRNA gene of said bacterium includes sequence SEQ ID NO: 1, and wherein the bacterial extract is obtained after treatment of said bacterial suspension in such a way as to eliminate intracellular components. 4. Bacterial extract according to claim 3 , wherein said intracellular components include at least nucleic acids. 5. Bacterial extract according to claim 3 , wherein it includes a fraction E0 comprising at least membrane proteins, periplasmic proteins and proteins arising from the flagellum. 6. Bacterial extract according to claim 5 , wherein said membrane proteins consist of porins, OmpA, lipopolysaccharides and/or lipoproteins. 7. Bacterial extract according to claim 3 , wherein it includes a fraction SO comprising at least secreted peptides and proteins and secondary metabolites. 8. Bacterial extract according to claim 3 , wherein it includes a fraction ESO comprising at least fraction E0 and fraction SO. 9. Bacterial extract according to claim 8 , wherein said fraction ESO has a protein profile, obtained by SDS-PAGE, which includes three principal bands corresponding to molecular weights ranging between 30 kDa and 36 kDa, 41 kDa and 45 kDa, and 47 kDa and 51 kDa, respectively. 10. Composition comprising at least, as an active ingredient, a bacterial extract according to claim 3 . 11. Composition according to claim 10 , for the treatment of gastrointestinal and oral inflammatory diseases. 12. Composition according to claim 11 , wherein said gastrointestinal and oral inflammatory diseases consist of Crohn's disease, colitis or periodontitis. 13. Composition according claim 10 , wherein further comprising a pharmaceutically acceptable carrier. 14. Method of activating TLR2, TLR4 and/or TLR5 which comprises contacting cells expressing TLR2, TLR4 and/or TLR5 with a bacterial extract of claim 1 . 15. Method of inhibiting PAR2 activation, which comprises contacting cells expressing PAR2 with a bacterial extract of claim 7 .

Assignees

Inventors

Classifications

  • Immunomodulators · CPC title

  • Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

  • Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] · CPC title

  • A61K35/74Primary

    Bacteria (therapeutic use of a bacterial protein A61K38/00) · CPC title

  • Neisseria · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US9486486B2 cover?
The present invention relates to a novel bacterial strain isolated and characterized from groundwater. The invention also relates to bacterial extracts and to the therapeutic use of same, notably in the context of the treatment of inflammations.
Who is the assignee on this patent?
Castex-Rizzi Nathalie, Nguyen Thien, Libon Christine, and 3 more
What technology area does this patent fall under?
Primary CPC classification A61K35/74. Mapped technology areas include Human Necessities.
When was this patent published?
Publication date Tue Nov 08 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).